Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Two Stocks Showing Signs of Overvaluation

Published 2024-01-12, 02:15 a/m
Updated 2024-01-12, 09:15 a/m
© Reuters.  Two Stocks Showing Signs of Overvaluation

Kalkine Media - In the midst of an uncertain and volatile macroeconomic environment, the technology sector has witnessed a substantial surge in 2023. The resulting rally has led to increased valuations for several tech companies, raising concerns about potential overvaluation. Here are two TSX tech stocks that may face a significant pullback if market sentiment takes a bearish turn.

Kinaxis (TSX:KXS) Stock:

Kinaxis (TSX:KXS), valued at $4.1 billion, stands out as one of Canada's fastest-growing companies. Since its IPO in June 2014, Kinaxis has delivered an impressive 1,000% return to shareholders, even though the stock currently trades around 40% below its all-time highs.

Specializing in cloud-based subscription software for supply chain operations, Kinaxis serves enterprise clients globally, offering solutions such as sales and operations planning, inventory management, and control center services. In Q3 2023, the company reported a 21% YoY increase in sales to US$108 million, with adjusted EBITDA growing by 54% to US$22.8 million.

Despite strong financial performance, Kinaxis trades at a relatively high valuation, with a forward price-to-earnings (P/E) ratio of 52.3 and a price-to-sales (P/S) ratio of six. While analysts remain bullish, predicting a 51% surge in the next 12 months, investors should exercise caution due to the lofty multiples.

Docebo (TSX:DCBO) Stock:

Another high-growth tech stock, Docebo (TSX:DCBO), has shown remarkable performance since its IPO in late 2019, delivering a 295% gain to shareholders. However, the stock is currently down 46% from its all-time highs, presenting potential concerns.

In Q3 2023, Docebo reported a 26% YoY increase in sales to US$46.5 million, with subscription sales accounting for 94% of the top line. The company ended the quarter with annual recurring revenue (ARR) of US$181.8 million. Despite these positive metrics, Docebo trades at a premium, with a forward P/E ratio of 83 and a forward P/S ratio of 6.2.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

While Docebo has focused on improving its bottom line, with forecasted adjusted earnings of $0.77 per share in 2024, investors should carefully consider the premium valuation. The stock's current pricing suggests the need for caution, especially in a market environment where sentiment may shift.

Investors evaluating these tech stocks should be mindful of the potential for a pullback, given their elevated valuations. Conducting thorough due diligence and considering risk factors will be essential for making informed investment decisions in the tech sector.

Read more on Kalkine Media

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.